Skip to content

Omeros OMER Debt-to-equity

Discontinued — last reported Q4 '22

Debt-to-equity at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0.0×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
0.1×-7.2×
Immunome logo
ImmunomeIMNM
0.0×
Vor Biopharma logo
Vor BiopharmaVOR
0.5×+0.2×
Annexon logo
AnnexonANNX
0.1×0.0×
Arcus Biosciences logo
Arcus BiosciencesRCUS
0.2×+0.1×

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Current ratio+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

Based on the most recent quarter.

The official record: Omeros’s 10-Q, filed August 9, 2023, on SEC EDGAR. View the filing →

Ask your AI about Omeros's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's debt-to-equity?
Omeros (OMER) reported debt-to-equity of 0.3× in Q4 2022.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.